An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa

Background Hidradenitis suppurativa (HS) is a chronic inflammatory disorder characterized by sterile abscesses and fistulae predominantly affecting the axillae and groin. Various biologic agents have been attempted for HS, but there is still no definitive treatment. Objectives We sought to evaluate...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American Academy of Dermatology 2014-02, Vol.70 (2), p.243-251
Hauptverfasser: Leslie, Kieron S., DTM&H, FRCP, Tripathi, Shivani V., MD, Nguyen, Tien V., MD, Pauli, Mariela, MS, Rosenblum, Michael D., MD, PhD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 251
container_issue 2
container_start_page 243
container_title Journal of the American Academy of Dermatology
container_volume 70
creator Leslie, Kieron S., DTM&H, FRCP
Tripathi, Shivani V., MD
Nguyen, Tien V., MD
Pauli, Mariela, MS
Rosenblum, Michael D., MD, PhD
description Background Hidradenitis suppurativa (HS) is a chronic inflammatory disorder characterized by sterile abscesses and fistulae predominantly affecting the axillae and groin. Various biologic agents have been attempted for HS, but there is still no definitive treatment. Objectives We sought to evaluate the efficacy, safety, and tolerability of anakinra in the treatment of moderate to severe HS. Methods Six patients with moderate to severe HS were enrolled in an open-label study with all patients receiving active treatment for 8 weeks with an additional 8 weeks of follow-up off therapy. Results The 5 patients who completed the 8-week therapy showed a significant mean decrease in their modified Sartorius score of 34.8 points. The physician and patient global assessment of overall activity showed significant reductions between baseline and 8 weeks of therapy: 45.8 points and 35.6 points, respectively. The Dermatology Life Quality Index showed a significant reduction after 8 weeks of treatment with anakinra. Functional T-cell analysis revealed that patients had increased percentages of CD3+ T cells in lesional skin compared with nonlesional skin before therapy. Limitations The limited number of patients and lack of control group are limitations. Conclusions Anakinra demonstrated decreased HS disease activity by both objective and subjective measures.
doi_str_mv 10.1016/j.jaad.2013.09.044
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1490899092</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0190962213010402</els_id><sourcerecordid>1490899092</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-47bc94c624e9bff3a78e2b3bf21befea53a358c16bb9bbbdd2204e0a335a22f03</originalsourceid><addsrcrecordid>eNp9kU2L1TAUhoMozp3RP-BCsnTTevJx2wZEGAZ1hAEX6jrk45RJp02vSXrh_ht_i7_Mlju6cOEqcPK8L5znEPKKQc2ANW-HejDG1xyYqEHVIOUTsmOg2qppu_Yp2QFTUKmG8wtymfMAAEqK9jm54FIw2bXNjpjrSOcDxmo0Fkeay-JPdO6pieYhxGRoPyda7pGWhKZMGMv6--vnNHtMpqzjmWY8YkJ6H3wyHmMoIdO8HA7LCoSjeUGe9WbM-PLxvSLfP374dnNb3X359Pnm-q5ykrFSydY6JV3DJSrb98K0HXIrbM-ZxR7NXhix7xxrrFXWWu85B4lghNgbznsQV-TNufeQ5h8L5qKnkB2Oo4k4L1kzqaBTChRfUX5GXZpzTtjrQwqTSSfNQG9q9aA3tXpTq0HpVe0aev3Yv9gJ_d_IH5cr8O4M4LrlMWDS2QWMDn1I6Ir2c_h___t_4m4MMTgzPuAJ8zAvKa7-NNOZa9Bft-Nut2UCGEjg4jfsJ6Gh</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1490899092</pqid></control><display><type>article</type><title>An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Leslie, Kieron S., DTM&amp;H, FRCP ; Tripathi, Shivani V., MD ; Nguyen, Tien V., MD ; Pauli, Mariela, MS ; Rosenblum, Michael D., MD, PhD</creator><creatorcontrib>Leslie, Kieron S., DTM&amp;H, FRCP ; Tripathi, Shivani V., MD ; Nguyen, Tien V., MD ; Pauli, Mariela, MS ; Rosenblum, Michael D., MD, PhD</creatorcontrib><description>Background Hidradenitis suppurativa (HS) is a chronic inflammatory disorder characterized by sterile abscesses and fistulae predominantly affecting the axillae and groin. Various biologic agents have been attempted for HS, but there is still no definitive treatment. Objectives We sought to evaluate the efficacy, safety, and tolerability of anakinra in the treatment of moderate to severe HS. Methods Six patients with moderate to severe HS were enrolled in an open-label study with all patients receiving active treatment for 8 weeks with an additional 8 weeks of follow-up off therapy. Results The 5 patients who completed the 8-week therapy showed a significant mean decrease in their modified Sartorius score of 34.8 points. The physician and patient global assessment of overall activity showed significant reductions between baseline and 8 weeks of therapy: 45.8 points and 35.6 points, respectively. The Dermatology Life Quality Index showed a significant reduction after 8 weeks of treatment with anakinra. Functional T-cell analysis revealed that patients had increased percentages of CD3+ T cells in lesional skin compared with nonlesional skin before therapy. Limitations The limited number of patients and lack of control group are limitations. Conclusions Anakinra demonstrated decreased HS disease activity by both objective and subjective measures.</description><identifier>ISSN: 0190-9622</identifier><identifier>EISSN: 1097-6787</identifier><identifier>DOI: 10.1016/j.jaad.2013.09.044</identifier><identifier>PMID: 24314876</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; anakinra ; Dermatology ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Follow-Up Studies ; hidradenitis suppurativa ; Hidradenitis Suppurativa - diagnosis ; Hidradenitis Suppurativa - drug therapy ; Humans ; inflammation ; Injections, Subcutaneous ; Interleukin 1 Receptor Antagonist Protein - administration &amp; dosage ; interleukin-1 ; Male ; Patient Satisfaction - statistics &amp; numerical data ; Pilot Projects ; Prospective Studies ; Quality of Life ; Severity of Illness Index ; T cells ; treatment ; Treatment Outcome</subject><ispartof>Journal of the American Academy of Dermatology, 2014-02, Vol.70 (2), p.243-251</ispartof><rights>American Academy of Dermatology, Inc.</rights><rights>2013 American Academy of Dermatology, Inc.</rights><rights>Copyright © 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-47bc94c624e9bff3a78e2b3bf21befea53a358c16bb9bbbdd2204e0a335a22f03</citedby><cites>FETCH-LOGICAL-c411t-47bc94c624e9bff3a78e2b3bf21befea53a358c16bb9bbbdd2204e0a335a22f03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jaad.2013.09.044$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24314876$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Leslie, Kieron S., DTM&amp;H, FRCP</creatorcontrib><creatorcontrib>Tripathi, Shivani V., MD</creatorcontrib><creatorcontrib>Nguyen, Tien V., MD</creatorcontrib><creatorcontrib>Pauli, Mariela, MS</creatorcontrib><creatorcontrib>Rosenblum, Michael D., MD, PhD</creatorcontrib><title>An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa</title><title>Journal of the American Academy of Dermatology</title><addtitle>J Am Acad Dermatol</addtitle><description>Background Hidradenitis suppurativa (HS) is a chronic inflammatory disorder characterized by sterile abscesses and fistulae predominantly affecting the axillae and groin. Various biologic agents have been attempted for HS, but there is still no definitive treatment. Objectives We sought to evaluate the efficacy, safety, and tolerability of anakinra in the treatment of moderate to severe HS. Methods Six patients with moderate to severe HS were enrolled in an open-label study with all patients receiving active treatment for 8 weeks with an additional 8 weeks of follow-up off therapy. Results The 5 patients who completed the 8-week therapy showed a significant mean decrease in their modified Sartorius score of 34.8 points. The physician and patient global assessment of overall activity showed significant reductions between baseline and 8 weeks of therapy: 45.8 points and 35.6 points, respectively. The Dermatology Life Quality Index showed a significant reduction after 8 weeks of treatment with anakinra. Functional T-cell analysis revealed that patients had increased percentages of CD3+ T cells in lesional skin compared with nonlesional skin before therapy. Limitations The limited number of patients and lack of control group are limitations. Conclusions Anakinra demonstrated decreased HS disease activity by both objective and subjective measures.</description><subject>Adult</subject><subject>anakinra</subject><subject>Dermatology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>hidradenitis suppurativa</subject><subject>Hidradenitis Suppurativa - diagnosis</subject><subject>Hidradenitis Suppurativa - drug therapy</subject><subject>Humans</subject><subject>inflammation</subject><subject>Injections, Subcutaneous</subject><subject>Interleukin 1 Receptor Antagonist Protein - administration &amp; dosage</subject><subject>interleukin-1</subject><subject>Male</subject><subject>Patient Satisfaction - statistics &amp; numerical data</subject><subject>Pilot Projects</subject><subject>Prospective Studies</subject><subject>Quality of Life</subject><subject>Severity of Illness Index</subject><subject>T cells</subject><subject>treatment</subject><subject>Treatment Outcome</subject><issn>0190-9622</issn><issn>1097-6787</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU2L1TAUhoMozp3RP-BCsnTTevJx2wZEGAZ1hAEX6jrk45RJp02vSXrh_ht_i7_Mlju6cOEqcPK8L5znEPKKQc2ANW-HejDG1xyYqEHVIOUTsmOg2qppu_Yp2QFTUKmG8wtymfMAAEqK9jm54FIw2bXNjpjrSOcDxmo0Fkeay-JPdO6pieYhxGRoPyda7pGWhKZMGMv6--vnNHtMpqzjmWY8YkJ6H3wyHmMoIdO8HA7LCoSjeUGe9WbM-PLxvSLfP374dnNb3X359Pnm-q5ykrFSydY6JV3DJSrb98K0HXIrbM-ZxR7NXhix7xxrrFXWWu85B4lghNgbznsQV-TNufeQ5h8L5qKnkB2Oo4k4L1kzqaBTChRfUX5GXZpzTtjrQwqTSSfNQG9q9aA3tXpTq0HpVe0aev3Yv9gJ_d_IH5cr8O4M4LrlMWDS2QWMDn1I6Ir2c_h___t_4m4MMTgzPuAJ8zAvKa7-NNOZa9Bft-Nut2UCGEjg4jfsJ6Gh</recordid><startdate>20140201</startdate><enddate>20140201</enddate><creator>Leslie, Kieron S., DTM&amp;H, FRCP</creator><creator>Tripathi, Shivani V., MD</creator><creator>Nguyen, Tien V., MD</creator><creator>Pauli, Mariela, MS</creator><creator>Rosenblum, Michael D., MD, PhD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140201</creationdate><title>An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa</title><author>Leslie, Kieron S., DTM&amp;H, FRCP ; Tripathi, Shivani V., MD ; Nguyen, Tien V., MD ; Pauli, Mariela, MS ; Rosenblum, Michael D., MD, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-47bc94c624e9bff3a78e2b3bf21befea53a358c16bb9bbbdd2204e0a335a22f03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>anakinra</topic><topic>Dermatology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>hidradenitis suppurativa</topic><topic>Hidradenitis Suppurativa - diagnosis</topic><topic>Hidradenitis Suppurativa - drug therapy</topic><topic>Humans</topic><topic>inflammation</topic><topic>Injections, Subcutaneous</topic><topic>Interleukin 1 Receptor Antagonist Protein - administration &amp; dosage</topic><topic>interleukin-1</topic><topic>Male</topic><topic>Patient Satisfaction - statistics &amp; numerical data</topic><topic>Pilot Projects</topic><topic>Prospective Studies</topic><topic>Quality of Life</topic><topic>Severity of Illness Index</topic><topic>T cells</topic><topic>treatment</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Leslie, Kieron S., DTM&amp;H, FRCP</creatorcontrib><creatorcontrib>Tripathi, Shivani V., MD</creatorcontrib><creatorcontrib>Nguyen, Tien V., MD</creatorcontrib><creatorcontrib>Pauli, Mariela, MS</creatorcontrib><creatorcontrib>Rosenblum, Michael D., MD, PhD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American Academy of Dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Leslie, Kieron S., DTM&amp;H, FRCP</au><au>Tripathi, Shivani V., MD</au><au>Nguyen, Tien V., MD</au><au>Pauli, Mariela, MS</au><au>Rosenblum, Michael D., MD, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa</atitle><jtitle>Journal of the American Academy of Dermatology</jtitle><addtitle>J Am Acad Dermatol</addtitle><date>2014-02-01</date><risdate>2014</risdate><volume>70</volume><issue>2</issue><spage>243</spage><epage>251</epage><pages>243-251</pages><issn>0190-9622</issn><eissn>1097-6787</eissn><abstract>Background Hidradenitis suppurativa (HS) is a chronic inflammatory disorder characterized by sterile abscesses and fistulae predominantly affecting the axillae and groin. Various biologic agents have been attempted for HS, but there is still no definitive treatment. Objectives We sought to evaluate the efficacy, safety, and tolerability of anakinra in the treatment of moderate to severe HS. Methods Six patients with moderate to severe HS were enrolled in an open-label study with all patients receiving active treatment for 8 weeks with an additional 8 weeks of follow-up off therapy. Results The 5 patients who completed the 8-week therapy showed a significant mean decrease in their modified Sartorius score of 34.8 points. The physician and patient global assessment of overall activity showed significant reductions between baseline and 8 weeks of therapy: 45.8 points and 35.6 points, respectively. The Dermatology Life Quality Index showed a significant reduction after 8 weeks of treatment with anakinra. Functional T-cell analysis revealed that patients had increased percentages of CD3+ T cells in lesional skin compared with nonlesional skin before therapy. Limitations The limited number of patients and lack of control group are limitations. Conclusions Anakinra demonstrated decreased HS disease activity by both objective and subjective measures.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>24314876</pmid><doi>10.1016/j.jaad.2013.09.044</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0190-9622
ispartof Journal of the American Academy of Dermatology, 2014-02, Vol.70 (2), p.243-251
issn 0190-9622
1097-6787
language eng
recordid cdi_proquest_miscellaneous_1490899092
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Adult
anakinra
Dermatology
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Follow-Up Studies
hidradenitis suppurativa
Hidradenitis Suppurativa - diagnosis
Hidradenitis Suppurativa - drug therapy
Humans
inflammation
Injections, Subcutaneous
Interleukin 1 Receptor Antagonist Protein - administration & dosage
interleukin-1
Male
Patient Satisfaction - statistics & numerical data
Pilot Projects
Prospective Studies
Quality of Life
Severity of Illness Index
T cells
treatment
Treatment Outcome
title An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T03%3A08%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20open-label%20study%20of%20anakinra%20for%20the%20treatment%20of%C2%A0moderate%20to%20severe%20hidradenitis%20suppurativa&rft.jtitle=Journal%20of%20the%20American%20Academy%20of%20Dermatology&rft.au=Leslie,%20Kieron%20S.,%20DTM&H,%20FRCP&rft.date=2014-02-01&rft.volume=70&rft.issue=2&rft.spage=243&rft.epage=251&rft.pages=243-251&rft.issn=0190-9622&rft.eissn=1097-6787&rft_id=info:doi/10.1016/j.jaad.2013.09.044&rft_dat=%3Cproquest_cross%3E1490899092%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1490899092&rft_id=info:pmid/24314876&rft_els_id=S0190962213010402&rfr_iscdi=true